Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan

被引：0
|
作者：
Podder, Vivek
Ranjan, Tulika
Bardhan, Mainak
McCracken, Andrea
Hurmiz, Charlie
Ganiyani, Mohammad Arfat
Ahmad, Shahzaib
Mahtani, Reshma L.
Ahluwalia, Manmeet Singh
机构：
[1] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[2] Guardian Res Network, Spartanburg, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1036
引用
收藏
页数：1
相关论文
共 50 条
  • [1] DIFFERENTIAL SURVIVAL IMPACT OF TRASTUZUMAB DERUXTECAN IN HER2-POSITIVE VERSUS HER2-LOW BREAST CANCER PATIENTS WITH BRAIN METASTASES
    Ranjan, Tulika
    Podder, Vivek
    Bardhan, Mainak
    Mccracken, Andrea
    Hurmiz, Charlie
    Mahtani, Reshma L.
    Ahluwalia, Manmeet Singh
    NEURO-ONCOLOGY, 2024, 26
  • [2] Concurrent Use of Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer
    Bouziane, Jihane
    Loap, Pierre
    Cao, Kim
    Allali, Sofiane
    Gounane, Yacine
    Loganadane, Gokoulakrichenane
    Escalup, Laurence
    Pierga, Jean-Yves
    Kirova, Youlia
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (12): : 580 - 584
  • [3] The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with carcinomatosis
    Batista, Marta Vaz
    Perez-Garcia, Jose Manuel
    Garrigos, Laia
    Garcia-Saenz, Jose Angel
    Cortez, Patricia
    Racca, Fabricio
    Blanch, Salvador
    Ruiz-Borrego, Manuel
    Fernandez-Ortega, Adela
    Fernandez Abad, Maria
    Iranzo, Vega
    Gion, Maria
    Martrat, Griselda
    Alcala-Lopez, Daniel
    Perez-Escuredo, Jhudit
    Sampayo-Cordero, Miguel
    Llombart-Cussac, Antonio
    Braga, Sofia
    Cortes, Javier
    MED, 2025, 6 (01):
  • [4] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [5] Real World Data for Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases
    Toler, Andrew
    Bobolts, Laura R.
    Mangurian, Mark
    Pozotrigo, Melissa
    Wise, Corey
    Solomon, Hiywete
    Hartung, Nicole
    Makielski, Rory
    Marur, Shika
    Ravindranathan, Meera
    Marur, Shanthi
    CANCER RESEARCH, 2023, 83 (05)
  • [6] Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer
    Shimomura, Akihiko
    Takano, Toshimi
    Takahashi, Shunji
    Sagara, Yasuaki
    Watanabe, Junichiro
    Tokunaga, Eriko
    Shinkai, Tetsu
    Kamio, Takahiro
    Kikumori, Kunika
    Kamiyama, Emi
    Fujisaki, Yoshihiko
    Saotome, Dan
    Yamashita, Toshinari
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (01) : 160 - 169
  • [7] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Ferhanoglu, Burhan
    Atesoglu, Elif Birtas
    Ozbalak, Murat
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12) : 1147 - 1147
  • [8] Trastuzumab Deruxtecan in cerebral metastatic HER2-positive Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04) : 354 - 354
  • [9] Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
    Jerusalem, Guy
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Farre, Xavier Gonzalez
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R.
    Murthy, Rashmi K.
    Gianni, Lorenzo
    Takano, Toshimi
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb
    Perrin, Christophe
    CANCER DISCOVERY, 2022, 12 (12) : 2754 - 2762
  • [10] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
12345